Is VCYT a good stock to buy?
Veracyte, Inc. · end-of-day data as of Nov 13, 2026
- PT$54.14 +122.5%
- ConsensusBuy · 14
- P/E vs own-58.8%
- P/E vs sector-51.0%
- FCF yield+8.2%
- RSI28
- Sector▲ +15.9%
- Earnings in103d
- P/E15.8x
- Support-4.4%
- Resistance+8.5%
- Off 52w high-60.1%
- Volume0.8x
- Bollingerlower half
- News0.00
- Trendsideways
- 52w range$22–$61
- ATR+14.5%
- Off ATH-71.7%
- Insiders-$2.86M
- MAs0 of 4
- MA20×50Death 3d ago
- MACD-2.50
Updates with the 15-min delayed price. Not a forecast or investment advice.
Is Veracyte a good stock to buy?
Veracyte is strong on 3 of the 4 questions about the business. The price is low: 15.8 times its earnings, below its 3-year median of 62.1 (Nov 13, 2026). pretickt does not say whether to buy or sell.
VCYT sales growth revenue growth
+20%a year, for the last 3 yearsVeracyte's sales grew 20% a year for 3 years, to $517M in fiscal 2025.
VCYT analysts' forecast revenue estimates
+14%the sales they expect next fiscal year, on the lastAnalysts expect Veracyte's sales to grow 14% to $592M in fiscal 2026 (6 analysts).
VCYT competitors
pretickt analysis+17%its sales in 12 months, on a year before
Veracyte's sales grew 17% in the 12 months to Sep 30, 2026, faster than Quest Diagnostics (+9%), Labcorp (+6%), Revvity (+5%) and Charles River Laboratories (-1%).
VCYT sales by business revenue by segment
95%of its sales from TestingTesting brought Veracyte 95% of its sales in fiscal 2025; Product 3%.
VCYT earnings vs estimates
4 of 5quarters above the analysts' estimateVeracyte beat the analysts' profit estimate in 4 of 5 quarters, the latest on Nov 4, 2026; 3 quarters with one-time gains or charges are left out.
VCYT insider selling
-$19.25Msold, net, by its executives in 12 monthsVeracyte's executives and directors sold a net $19.25M of shares in the 12 months to Nov 13, 2026; none bought.
VCYT number of employees
-8%fewer people in a yearVeracyte had 755 employees at the end of fiscal 2025, 8% fewer than a year before.
VCYT CEO pay
$7.42Mfor fiscal 2025, 79% of it in stock and optionsVeracyte paid its CEO $7.42M for fiscal 2025, 79% of it in stock and options.
VCYT financial health Altman Z-score
9.1Altman Z-score, safe above 3Veracyte's Altman Z-score is 9.1 (Nov 13, 2026), above 3, where the safe zone starts.
VCYT quality checks Piotroski score
7 of 9checks passedVeracyte passes 7 of the 9 Piotroski checks in the 12 months to Sep 30, 2026; it misses on the current ratio and new shares.
VCYT price vs profit P/E ratio
15.8×a year's earningsVeracyte's P/E ratio is 15.8 (Nov 13, 2026), below its 3-year median of 62.1.
VCYT price vs competitors
pretickt analysis15.8×a year's earnings, against its competitorsInvestors pay 15.8 times Veracyte's earnings (Nov 13, 2026), less than for Charles River Laboratories (371.4), Revvity (68.3), Labcorp (30.4) or Quest Diagnostics (25.9).
VCYT analysts' target price target
+123%to their average targetAnalysts' average price target for Veracyte is $54.14, 123% above the Nov 13, 2026 close of $24.33.
VCYT analyst ratings, 90 days
pretickt analysisLeerink Partnersdowngrade
In the 90 days to Nov 13, 2026, Leerink Partners downgraded Veracyte.
What is Veracyte's P/E ratio?
Veracyte's P/E ratio is 15.8 (Nov 13, 2026), below its 3-year median of 62.1. Investors pay 15.8 times Veracyte's earnings (Nov 13, 2026), less than for Charles River Laboratories (371.4), Revvity (68.3), Labcorp (30.4) or Quest Diagnostics (25.9).
Who are Veracyte's biggest competitors?
pretickt compares Veracyte with Charles River Laboratories, Revvity, Quest Diagnostics and Labcorp. Veracyte's sales grew 17% in the 12 months to Sep 30, 2026, faster than Quest Diagnostics (+9%), Labcorp (+6%), Revvity (+5%) and Charles River Laboratories (-1%).
Who is dumping Veracyte stock?
Veracyte's executives and directors sold a net $19.25M of shares in the 12 months to Nov 13, 2026; none bought.
How does Veracyte make money?
Testing brought Veracyte 95% of its sales in fiscal 2025; Product 3%.
How many employees does Veracyte have?
Veracyte had 755 employees at the end of fiscal 2025, 8% fewer than a year before.
From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.